Thymosin Alpha-1: What the Trial Data Actually Shows
A 28-amino-acid peptide isolated from thymic tissue in 1977, thymosin alpha-1 has been studied for nearly five decades as an immune modulator, with real randomized trial data in chronic hepatitis B, as a chemotherapy adjunct in lung cancer, as postoperative adjuvant therapy in hepatitis-B-related liver cancer, and in vaccine response in older adults, alongside a COVID-19 evidence base that turned out more contested than its pandemic-era reputation suggests.
An Immune Modulator, and Not the Same Thing as TB-500
Thymosin alpha-1 and thymosin beta-4, marketed as TB-500 and covered in this site's own guide, share a name and a thymic origin and nothing else clinically relevant. Thymosin alpha-1 is a 28-amino-acid peptide that acts on the immune system: toll-like receptor signaling, dendritic cell maturation, T-cell differentiation. Thymosin beta-4 is a 43-amino-acid peptide that acts on the cytoskeleton and tissue repair. This guide covers thymosin alpha-1 only, and none of the tissue-repair or anti-fibrotic evidence in the Thymosin Beta-4 (TB-500) guide applies here, or the reverse.
An Immune Thermostat, Not a One-Direction Booster
Thymosin alpha-1 was isolated from calf thymus tissue in 1977 as one of the active components of thymosin fraction 5, the extract researchers were studying for its effects on T-cell maturation (Goldstein et al. 1977). It acts through toll-like receptors 4 and 9 to enhance pathogen recognition, promotes dendritic cell maturation and antigen presentation, and supports CD4+ and CD8+ T-cell maturation and survival. It also upregulates MHC class I expression at the transcriptional level, an effect first characterized across thyroid, tumor, and macrophage cell lines, where surface MHC-I expression peaked at roughly 150% of control values 12 hours after exposure through increased binding of a p50/Fra-2 transcription-factor complex to the MHC-I gene's enhancer-A region (Giuliani et al. 2000). Its cytokine effects are genuinely context-dependent rather than uniformly anti-inflammatory: in ex vivo blood cells from COVID-19 patients, it reduced TNF-alpha, IL-1beta, IL-6, and CCL2 expression while increasing the anti-inflammatory cytokine IL-10 (Matteucci et al. 2021), while a pooled analysis of randomized sepsis trials found a significant reduction in TNF-alpha (SMD -0.47, P=.002) but no significant overall effect on IL-6 (SMD -0.32, P=.49) (Liu F et al. 2016). Its most clinically distinctive property is bidirectional: in an underactive immune system it tends to upregulate immune activity, and in an overactive or dysregulated one it has been described in the immunology literature as helping restore balance rather than simply adding more stimulation. That bidirectional "immune thermostat" framing describes a real and well-documented mechanism; it is not the same thing as a confirmed clinical benefit in a specific autoimmune condition, which Honest Limits below addresses directly.
One claim worth addressing directly, since it appears in some clinical training materials: that thymosin alpha-1 is a senolytic that clears senescent cells by raising MHC-I expression and recruiting NK cells to kill them. The individual pieces are separately real, MHC-I upregulation as above, and documented support for NK-cell and cytotoxic T-cell function, but no primary study demonstrates that specific sequence for thymosin alpha-1, MHC-I upregulation on senescent cells leading to NK-mediated clearance of those cells. There's also a physiological problem with the proposed mechanism itself: classical MHC-I engagement typically signals inhibitory NK receptors, which dampens rather than triggers NK-cell killing, the "missing-self" model that has been standard immunology for decades. MHC-I upregulation is much better established as enhancing recognition by CD8+ cytotoxic T cells through antigen presentation, not NK-cell killing. The better-supported version of the underlying idea is immunosenescence, not senolysis: aging involves thymic involution, reduced naive T-cell output, and T-cell exhaustion, and thymosin alpha-1 has documented human trial effects on that specific cluster, including the vaccine-response data below, which is a real and more defensible claim than "senolytic."
Thymosin alpha-1 is marketed and prescribed in more than 30 countries under the brand name Zadaxin (thymalfasin) for chronic hepatitis B and C and as a cancer and vaccine adjuvant, but it is not FDA-approved for any indication in the United States.
Evidence Summary
What the Trials Actually Show, Indication by Indication
Chronic Hepatitis B, Head-to-Head Against Interferon
Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, Huang P. "Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis." Antiviral Res. 2008;77(2):136-141. This meta-analysis pooled 4 randomized controlled trials (n=199) comparing thymosin alpha-1 (1.6 mg twice weekly) directly against interferon alpha (500 MU three times weekly) for a minimum of 24 weeks in HBV DNA-positive patients with elevated ALT. Immediately at the end of treatment, the two drugs performed similarly. At 6-month follow-up, thymosin alpha-1 showed a significantly higher rate of virological response, defined as loss of HBV DNA plus HBeAg loss in HBeAg-positive patients or HBV DNA loss alone in HBeAg-negative patients (OR 3.71, 95% CI 2.05-6.71, p<0.0001), biochemical response, normalized ALT (OR 3.12, 95% CI 1.74-5.62, p=0.0001), and complete response, both together (OR 2.69, 95% CI 1.47-4.91, p=0.001). Interferon alpha produced flu-like symptoms, fatigue, and other systemic side effects; thymosin alpha-1's only reported adverse effect was injection-site discomfort.
Meta-Analysis of 4 Human RCTs (n=199) · Endpoint: Virological, Biochemical, and Complete Response at 6-Month Follow-Up, Favoring Thymosin Alpha-1 Over Interferon AlphaChronic Hepatitis B, Added to Interferon: A Trial That Fell Just Short of Significance
Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, Suresh S, Wu YJ, Machin D, Lim CC, Fock KM, Koay E, Bowden S, Locarnini S, Ishaque SM. "A Randomized, Placebo-Controlled Trial of Thymosin-alpha1 and Lymphoblastoid Interferon for HBeAg-Positive Chronic Hepatitis B." Antivir Ther. 2006;11(2):245-254. This double-blind, randomized, placebo-controlled trial enrolled 98 HBeAg-positive chronic hepatitis B patients, randomizing 48 to lymphoblastoid interferon (5 MIU three times weekly) plus thymosin alpha-1 (1.6 mg three times weekly) and 50 to the same interferon regimen plus a thymosin placebo, for 24 weeks of treatment with 72 weeks of total follow-up. At 72 weeks, HBeAg loss occurred in 45.8% of the combination group versus 28.0% of the interferon-alone group, a 17.8 percentage-point difference (95% CI -1.2% to 35.3%, P=0.067) that the authors described as a potentially important difference requiring confirmation in subsequent trials rather than a confirmed benefit. Secondary endpoints, including HBeAg seroconversion, histologic change, ALT normalization, and HBV DNA loss, showed no statistically significant difference between groups.
Human RCT (n=98), Double-Blind, Randomized, Placebo-Controlled · Endpoint: HBeAg Loss at 72 Weeks, Trend Toward Benefit That Did Not Reach Statistical SignificanceNon-Small Cell Lung Cancer: An Adjunct to Chemotherapy
Jiang J, Wang X, Tian J, Li L, Lin Q. "Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials." Thorac Cancer. 2011;2(4):213-220. This systematic review pooled 10 randomized controlled trials (n=724, individual trials ranging from 42 to 200 patients) testing thymosin alpha-1 added to cisplatin-based chemotherapy (with either vinorelbine or gemcitabine) against chemotherapy alone. Adding thymosin alpha-1 to vinorelbine-cisplatin improved overall response rate (OR 1.86, 95% CI 1.08-3.20), tumor control rate (OR 3.06, 95% CI 1.36-6.88), one-year survival (OR 3.05, 95% CI 1.34-6.96), and quality of life (OR 3.39, 95% CI 1.54-7.47), alongside improved CD4+ and NK-cell counts and less thrombocytopenia. Adding it to gemcitabine-cisplatin showed a similar pattern: overall response rate (OR 1.67, 95% CI 1.09-2.55), tumor control rate (OR 2.38, 95% CI 1.01-5.62), and quality of life (OR 3.84, 95% CI 1.97-7.48), with improved immune markers and no increase in adverse effects. The review's authors were explicit that the reliability of these findings is limited by unclear risk of bias for randomization sequence generation and blinding across the underlying trials, all of which were conducted in China, so this evidence base is real and consistent but has not yet been independently replicated outside that trial program.
Meta-Analysis of 10 Human RCTs (n=724) · Endpoint: Response Rate, Tumor Control, Survival, and Immune Markers, Consistent Benefit With Acknowledged Trial-Quality LimitationsHepatocellular Carcinoma: Adjuvant Therapy After Curative Resection
He L, Xia Z, Peng W, He C, Li C, Wen T. "Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis." Medicine (Baltimore). 2021;100(20):e25749. This single-center retrospective study analyzed 468 patients with solitary HBV-related hepatocellular carcinoma after curative resection, using propensity score matching to control for confounding variables and reduce the analysis to 100 well-matched pairs, with a median follow-up of 60 months. Before matching, patients who received thymosin alpha-1 as adjuvant therapy had better recurrence-free survival (P=.018) and overall survival (P<.001); after matching, the same pattern held (recurrence-free survival P=.006, overall survival P<.001). On multivariate Cox regression, thymosin alpha-1 therapy remained an independent prognostic factor for both overall survival (HR 0.308, 95% CI 0.175-0.541, P<.001) and recurrence-free survival (HR 0.381, 95% CI 0.229-0.633, P<.001). Immunological response, measured by neutrophil-to-lymphocyte ratio and related markers, improved significantly more in the treatment group (P<.001), but virologic response, HBV DNA suppression and HBeAg loss or seroconversion, was similar between groups at 24 months. That combination is worth stating plainly: the survival advantage does not appear to be explained by better antiviral control, which points toward an immune-mediated mechanism rather than a purely antiviral one.
Retrospective Cohort With Propensity Score Matching (n=468, Matched to 100 Pairs) · Endpoint: Overall and Recurrence-Free Survival After Curative HCC Resection, Independent of Improved Antiviral ResponseInfluenza Vaccine Response in Older Men
Gravenstein S, Duthie EH, Miller BA, Roecker E, Drinka P, Prathipati K, Ershler WB. "Augmentation of Influenza Antibody Response in Elderly Men by Thymosin Alpha One: A Double-Blind Placebo-Controlled Clinical Study." J Am Geriatr Soc. 1989;37(1):1-8. This double-blind, randomized, placebo-controlled trial enrolled 90 men aged 65 to 99 (mean age 77.3), of whom 85 had sera acceptable for analysis, randomized to thymosin alpha-1 (900 mcg/m2 subcutaneously twice weekly for 8 doses) or placebo, given alongside the 1986 trivalent influenza vaccine. No toxicity was observed in either group. Antibody response, a four-fold rise in titer measured by ELISA over 3 to 6 weeks after vaccination, was significantly greater in the thymosin alpha-1 group at 6 weeks (P=.023). That overall difference was driven entirely by the older subgroup, men aged 77 and older (P=.039); no difference appeared between the younger treatment and placebo groups, and the older treated subjects produced antibody responses similar to the younger subjects overall. In other words, thymosin alpha-1 did not add benefit in men whose immune response to vaccination was already relatively intact; it specifically restored a more youthful antibody response in the oldest, most immunosenescent men.
Human RCT (n=85 Evaluable), Double-Blind, Randomized, Placebo-Controlled · Endpoint: Influenza Vaccine Antibody Response at 6 Weeks, Benefit Concentrated in the Oldest, Most Immunosenescent SubgroupCOVID-19: A Genuinely Contested Literature
Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells." Clin Infect Dis. 2020;71(16):2150-2157. In 76 patients with severe or critical COVID-19 in Wuhan (36 treated, 40 untreated), mortality was 11.1% in the treated group versus 30.0% in untreated patients (P=.044). Thymosin alpha-1 restored CD4+ and CD8+ T-cell counts in patients with marked lymphopenia (CD8+ <400/uL or CD4+ <650/uL), reduced the T-cell exhaustion markers PD-1 and Tim-3, and increased T-cell receptor excision circles, a marker of thymic output. Wu M, Ji J, Zhong L, et al. "Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study." Int Immunopharmacol. 2020;88:106873. In 334 critically ill patients across multiple centers, thymosin alpha-1 (1.6 mg once or twice daily for more than 5 days) was associated with substantially lower adjusted 28-day mortality in the critical-illness subgroup (HR 0.11, 95% CI 0.02-0.63, P=.013), but the authors were explicit that this benefit did not extend to 60-day mortality or overall survival time (P>.05), a distinction worth taking as seriously as the more favorable 28-day figure. Sun Q, Xie J, Zheng R, Li X, Chen H, Tong Z, Du B, Qiu H, Yang Y. "The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study." Int Immunopharmacol. 2021;90:107143. This is the important cautionary study in this literature: among 771 critically ill patients (327 treated), unadjusted analysis showed a large apparent mortality benefit (41.3% vs. 60.6%, P<.001), but after propensity-score matching to 522 well-balanced patients, that benefit disappeared entirely (51.0% vs. 52.9%, not significant), indicating the unadjusted result reflected which patients were selected for treatment rather than a true drug effect. Two meta-analyses published in 2023, pooling overlapping sets of these and other studies, reached opposite conclusions. Shang W, Zhang B, Ren Y, Wang W, Zhou D, Li Y. "Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes." Int Immunopharmacol. 2023;114:109584. Pooling 9 studies (5,352 patients), this analysis found no overall mortality benefit (RR 1.03, 95% CI 0.60-1.75, P=.92, I²=90%), with a subgroup signal in older and more severely ill patients. Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. "The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression." Inflammopharmacology. 2023;31:3317-3325. Pooling 8 studies, this analysis found a significant mortality benefit (RR 0.59, 95% CI 0.37-0.93, P=.02, I²=84%), with no significant difference in mechanical ventilation requirements or hospital length of stay. Both are legitimate systematic reviews built on overlapping but not identical study sets and different inclusion criteria; the honest reading is that this remains a genuinely unresolved question in the literature, not a settled one in either direction. A double-blind, placebo-controlled Phase III RCT (Shetty et al. 2022, Indian J Crit Care Med, approximately 105 patients) has also been cited in this literature with substantially more favorable figures. It has not yet been possible to access the primary source to verify its reported results independently, so no specific figures from that trial are stated here.
Individual Studies Show Real Effects; Two 2023 Meta-Analyses of Overlapping Data Reach Opposite Conclusions · Endpoint: Mortality, Genuinely Unresolved in the Current LiteratureWhat the Research Doesn't Yet Show
Thymosin alpha-1 is not FDA-approved for any indication in the United States. The strongest evidence for a specific clinical use sits in chronic hepatitis B, where multiple randomized trials show a real, measurable virological and biochemical advantage over or alongside interferon, though even that evidence base comes from a relatively small number of trials (4 head-to-head, plus the one placebo-controlled combination trial above) rather than a large modern registration program.
The lung cancer adjuvant data is a consistent, real signal across 10 randomized trials, but every one of those trials was conducted in China, and the review's own authors flagged unclear randomization and blinding quality across the trial set. The hepatocellular carcinoma adjuvant data is a single retrospective study, well-designed with propensity matching but from one center, and it awaits independent replication. Both are real signals, not yet settled evidence, and that's a meaningfully different claim.
The COVID-19 evidence is genuinely contested rather than settled in either direction, and this compound is sometimes described more confidently than the data support on both sides of that argument. Individual studies, including a real randomized signal, show meaningful mortality reductions in some populations; a larger, better-controlled study found the apparent benefit vanished after adjusting for which patients were selected for treatment; and the two most recent meta-analyses, published the same year and pooling overlapping data, reached opposite conclusions on overall mortality benefit. The honest summary is that thymosin alpha-1 may help a subset of severely ill COVID-19 patients, most plausibly those who are older or more severely lymphopenic, but the current literature does not support a confident claim of benefit, or a confident claim of no benefit, for COVID-19 as a whole.
No completed trial has tested thymosin alpha-1 for autoimmune disease as a category (outside chronic viral hepatitis specifically), or for lifespan, healthspan, or biological-aging endpoints in healthy adults. The mechanistic case for both is genuinely reasonable, thymosin alpha-1's immune-modulating and immune-tolerance-related effects plausibly bear on autoimmune conditions, and its effects on T-cell exhaustion and thymic-output markers plausibly bear on age-related immune decline, but plausible mechanism is not the same thing as demonstrated clinical benefit in either area, and current review-level support for both comes from narrative reviews rather than outcome trials against those specific endpoints. The one piece of this cluster with real randomized human data is narrower and more specific than either "autoimmune" or "longevity": restoring an impaired vaccine-antibody response in older adults, shown directly in the trial above. That's a genuine immunosenescence-related benefit, and a meaningfully different claim than "immune optimization" or "longevity" in a healthy adult of any age.
Thymosin alpha-1 should not be confused with thymosin beta-4 (TB-500), a different peptide with a different mechanism and a separate evidence base covered in this site's own guide.
How This Fits the Cellular Medicine Framework
Thymosin alpha-1 is one of the few compounds on this site with genuine randomized or well-matched human trial data behind multiple named indications, chronic hepatitis B, lung cancer adjuvant therapy, hepatocellular carcinoma adjuvant therapy, and vaccine response in older adults, rather than mechanism-only or animal-only support. That's a meaningfully stronger evidence position than most peptides discussed here. The honest complication is that its real trial data sits in a narrower set of uses than its broader reputation suggests, its most-discussed recent application, COVID-19, remains genuinely contested rather than resolved on rigorous re-analysis, and some of its most confidently marketed mechanisms, senolysis in particular, do not hold up against the immunology once traced back to a primary source. Both things can be true at once: a genuinely well-studied immune-modulating mechanism with real trial data behind several specific uses, and an evidence base that supports some of its uses far more strongly than others.
References
- Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, Lai CY, Chang D, Wang SS, Harvey C, Ramel AH, Meienhofer J. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. doi:10.1073/pnas.74.2.725 · PMID: 265536
- Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, Huang P. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis. Antiviral Res. 2008;77(2):136-141. doi:10.1016/j.antiviral.2007.10.014 · PMID: 18078676
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, Suresh S, Wu YJ, Machin D, Lim CC, Fock KM, Koay E, Bowden S, Locarnini S, Ishaque SM. A Randomized, Placebo-Controlled Trial of Thymosin-alpha1 and Lymphoblastoid Interferon for HBeAg-Positive Chronic Hepatitis B. Antivir Ther. 2006;11(2):245-254. doi:10.1177/135965350601100206 · PMID: 16640105
- Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Thorac Cancer. 2011;2(4):213-220. PMID: 27755854
- He L, Xia Z, Peng W, He C, Li C, Wen T. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore). 2021;100(20):e25749. doi:10.1097/MD.0000000000025749
- Gravenstein S, Duthie EH, Miller BA, Roecker E, Drinka P, Prathipati K, Ershler WB. Augmentation of Influenza Antibody Response in Elderly Men by Thymosin Alpha One: A Double-Blind Placebo-Controlled Clinical Study. J Am Geriatr Soc. 1989;37(1):1-8. doi:10.1111/j.1532-5415.1989.tb01561.x
- Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020;71(16):2150-2157. doi:10.1093/cid/ciaa630
- Wu M, Ji J, Zhong L, Shao Z, Xie Q, Liu Z, et al. Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Int Immunopharmacol. 2020;88:106873. doi:10.1016/j.intimp.2020.106873
- Sun Q, Xie J, Zheng R, Li X, Chen H, Tong Z, Du B, Qiu H, Yang Y. The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study. Int Immunopharmacol. 2021;90:107143. doi:10.1016/j.intimp.2020.107143
- Shang W, Zhang B, Ren Y, Wang W, Zhou D, Li Y. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Int Immunopharmacol. 2023;114:109584. doi:10.1016/j.intimp.2022.109584
- Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023;31:3317-3325. doi:10.1007/s10787-023-01354-2
- Matteucci C, Minutolo A, Balestrieri E, et al. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infect Dis. 2021;8(1):ofaa588. doi:10.1093/ofid/ofaa588
- Giuliani C, Saji M, Napolitano G, Palmer LA, Taniguchi SI, Shong M, Singer DS, Kohn LD. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30(3):778-786. PMID: 10741392
- Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis. 2016;16:488. doi:10.1186/s12879-016-1823-5
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.